Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 7/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1192875 | 0.92 | ALDH1A1 (0.47) | ALDH1A1CYP3A4CTSBMAPTTDP1 | |
| SCHEMBL351739 | 0.85 | ALDH1A1 (0.47) | ALDH1A1CYP3A4CTSBMAPTTDP1 | |
| SCHEMBL564506 | 0.84 | TDP1 (0.52) | ALDH1A1CYP3A4MAPTTDP1MEN1 | |
| SCHEMBL199359 | 0.84 | MAPT (0.52) | ALDH1A1CYP3A4MAPTTDP1MEN1 | |
| SCHEMBL29665784 | 0.84 | MAPT (0.52) | ALDH1A1CYP3A4MAPTTDP1MEN1 | |
| SCHEMBL7653551 | 0.84 | ALDH1A1 (0.53) | ALDH1A1CYP3A4CTSBMAPTTDP1 | |
| SCHEMBL30110723 | 0.84 | TDP1 (0.52) | ALDH1A1CYP3A4MAPTTDP1MEN1 | |
| SCHEMBL8095561 | 0.82 | MAPT (0.50) | ALDH1A1CYP3A4MAPTTDP1MEN1 | |
| SCHEMBL11550471 | 0.82 | ALDH1A1 (0.52) | ALDH1A1CYP3A4CTSBMAPTTDP1 | |
| SCHEMBL13609636 | 0.82 | ALDH1A1 (0.52) | ALDH1A1CYP3A4CTSBMAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746965-A1 | BENZIMIDAZOLES AS SIK-ACTIVITY MODULATORS | F. Hoffmann-La Roche AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| EP-4695256-A2 | ERBB2 INHIBITORS | Cogent Biosciences, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12492188-B2 | 1H-benzo[D]imidazole derivatives as TLR9 inhibitors for the treatment of fibrosis | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-12-09 | — | — | US | disclosed |
| EP-4642773-A1 | NEW BENZIMIDAZOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2025-11-05 | — | — | EP | disclosed |
| EP-4642535-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS SIK MODULATORS | F. Hoffmann-La Roche AG (CH) | 2025-11-05 | — | — | EP | disclosed |
| WO-2025111547-A1 | 2,3-DIHYDROPYROLLOPYRIDINE CARBOXAMIDE COMPOUNDS AND METHODS OF USE THEREOF | RGENTA THERAPEUTICS, INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| US-20250129078-A1 | ERBB2 INHIBITORS | COGENT BIOSCIENCES, INC. | 2025-04-24 | — | — | US | disclosed |
| WO-2025052129-A1 | PYRIDINE DERIVATIVES WHICH ACT AS INHIBITORS OF MPTP. | NRG THERAPEUTICS LTD (GB) | 2025-03-13 | — | — | WO | disclosed |
| CN-115490708-B | Sulfonamide macrocyclic derivative, preparation method and application thereof | 苏州亚盛药业有限公司 | 2025-01-24 | — | — | CN | disclosed |
| WO-2025017041-A1 | BENZIMIDAZOLES AS SIK-ACTIVITY MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2025-01-23 | — | — | WO | disclosed |
| US-7125877-B2 | Benzimidazole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-10-24 | — | — | US | disclosed |
| EP-1702919-A1 | NOVEL 2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-09-20 | — | — | EP | disclosed |
| EP-1505063-A1 | BENZIMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-02-09 | — | — | EP | disclosed |
| US-20030236267-A1 | Benzimidazole derivatives | MSD K.K. (JP) | 2003-12-25 | — | — | US | disclosed |
| EP-0647137-A4 | GLYCINE RECEPTOR ANTAGONISTS AND THE USE THEREOF. | UNIV CALIFORNIA WEBER ECKARD (US) | 1998-09-16 | — | — | EP | disclosed |
| US-5622952-A | NERVOUS SYSTEM DISORDERS; ADMINISTERING 1,4-DIHYDROQUINOXALINE-2,3-DIONE | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) | 1997-04-22 | — | — | US | disclosed |
| US-5620979-A | TREATING NEURONAL LOSS ASSOCIATED WITH STROKE, ISCHEMIA, CENTRAL NERVOUS SYSTEM TRAUMA, HYPOGLYCEMIA OR SURGERY | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) | 1997-04-15 | — | — | US | disclosed |
| US-5514680-A | ANTICONVULSANTS WITH 5,6,7-TRISUBSTITUTED-1,4-DIHYDROQUINOXALINE-2,3-DIONE | THE STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY (US) | 1996-05-07 | — | — | US | disclosed |
| EP-0647137-A1 | GLYCINE RECEPTOR ANTAGONISTS AND THE USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1995-04-12 | — | — | EP | disclosed |
| WO-1994000124-A1 | GLYCINE RECEPTOR ANTAGONISTS AND THE USE THEREOF | WEBER ECKARD (US) | 1994-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12492188-B2 | 1H-benzo[D]imidazole derivatives as TLR9 inhibitors for the treatment of fibrosis | TLR9, TLR1, TLR7 | ALDH1A1 1720/4885CYP3A4 4671/4885CTSB 1683/4885 |
| US-20030236267-A1 | Benzimidazole derivatives | OPRL1, GPR119, NPBWR1 | ALDH1A1 1636/4885CYP3A4 1862/4885CTSB 3443/4885 |
| US-20250129078-A1 | ERBB2 INHIBITORS | ERBB2, ERBB3, EGFR | ALDH1A1 4593/4885CYP3A4 2427/4885CTSB 1980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.